

CNMV
Edison, 4
28006 Madrid

Barcelona (Spain), March 23, 2017

RELEVANT FACT

Dear Sir,

In accordance with the Article 228 of Royal Legislative Decree 4/2015, dated 23 October, which enacts the consolidated text of the Securities Market Act, LABORATORIO REIG JOFRE SA ("Reig Jofre" or "the Company") submits hereafter press release on the marketing of three new injectable products for hospitals.

Adolf Rousaud
Secretary of the Board of Directors
Laboratorio Reig Jofre SA

Progress of the technological specialization segment

REIG JOFRE STARTS MARKETING OF THREE NEW INJECTABLE PRODUCTS FOR HOSPITALS

- Bivalirrudine, lyophilized injectable anticoagulant, indicated in adult patients who undergo a coronary intervention.
- Palonosetron, injectable antiemetic, indicated in the prevention of acute nausea and vomiting associated with chemotherapy.
- Cefepime, injectable antibiotic, indicated in the treatment of infections caused by bacteria

Barcelona, March 23, 2017. The pharmaceutical company Reig Jofre has recently started the commercialization of three new injectable products for hospitals, developed by the R&D team of the injectable and antibiotic plants that the company has in Barcelona and Toledo, respectively. These developments correspond to generic products based on specialized pharmaceutical technologies.

- **Bivalirrudine 250 mg** (active ingredient, Bivalirrudin) is a lyophilized injectable anticoagulant, indicated in both adult patients who undergo a percutaneous coronary intervention, including patients with myocardial infarction, and in the treatment of adult patients with unstable angina who will be subjected to an urgent or early surgery.

Bivalirrudine has been co-developed by the R&D team of the Barcelona injectable plant in collaboration with AMBIOPHARM, the North American developer and manufacturer of the active ingredient. The product is being registered in sixteen markets (United States among them) and is already being marketed in Spain, Denmark, Sweden, the United Kingdom and Australia. In the coming months, it is expected to start marketing this injectable in other countries.



- **Palonosetron 5 mg** (active ingredient, Palonosetron HCl) is an injectable antiemetic indicated for the prevention of acute nausea and vomiting associated with cancer chemotherapy in adults, adolescents and children over one month old.

Also, developed in the Barcelona injectable plant, Palonestron has been registered in six markets and is already being marketed in Spain, UK, Denmark and Sweden.

- **Cefepime 1g** (active ingredient, Cefepime-Arginine) is an injectable antibiotic belonging to cephalosporin group, indicated in the treatment of respiratory, urinary and gastric infections, among others, caused by bacteria. This injectable, developed by the R&D team of the Toledo penicillin plant, has been registered in Spain, where it is already marketed.

To market its developments, Reig Jofre has its own sales network in six European markets, and business relationships with 130 partners in 63 countries on five continents. The company confirms its firm commitment to internationalization, whose spearhead is the line of antibiotics and injectable products for hospitals, the latter strongly boosted in 2016 by the entry in Japan.

Get timely updates of Reig Jofre news by registering in the company's **subscription centre** on the corporate website: **www.reigjofre.com**

About Reig Jofre

Founded in Barcelona in 1929, Reig Jofre is a multinational pharmaceutical company with activity structured around two major axes: the main one, own-product manufacture and marketing (RJF Pharma, 80% of total sales) and a complementary one, development and manufacture for third parties (RJF CDMO, 20% of total sales). In its main activity, the company focuses on developing specialised technological products (antibiotics and solutions for injection); specialised therapeutic products for the dermatology, gynaecology and respiratory fields; and dietary supplements and consumer healthcare. The company focuses its R+D activity on developing new indications and/or pharmaceutical forms using known active substances, generic medicines with a particular focus on beta-lactam antibiotics and solutions for injection, topical dermatological products, OTCs and dietary supplements, and in addition develops new innovative molecules in partnership with start-ups and research centres.

Reig Jofre has over 900 employees, 4 development centres and 3 production centres in Europe, direct sales in 6 European countries and over 130 business partners in 63 countries across the world. The company closed 2016 with a turnover of 161 million euros.



Reig Jofre is listed on the Spanish Stock Exchange under the ticker RJF. Reig Jofre is listed on the Spanish Stock Exchange under the ticker RJF. Share capital: 63,214,220 shares.

For further information:

Investors and analysts

Gloria Folch

Tel. (+34) 93 480 67 10 – ext. 1241

gloria.folch@reigjofre.com

Media

Inma Santa-Pau

Tel. (+34) 93 480 67 10 – ext. 1242

inma.santapau@reigjofre.com